Nordic Star 2025 Pitch Competition 2
Pitch session 2 out of 2. SME finalists will give four-minute pitches of their companies in front of the pitch competition jury and the conference audience.
NLSDays Nordic Star is a pitch competition for Nordic life science SMEs. A selection of high-potential Nordic SMEs compete for the Nordic Star Award during each NLSDays conference.
Pitching Companies:
Loma Therapeutics 🇩🇰
In Loma Therapeutics, they are developing an immunotherapy (therapeutic vaccine) for the treatment of HPV-positive cancers. The immunotherapy is DNA-based and delivered via adenoviral vectors, which ensure an efficient activation of the patient’s immune system.
MucoLife Therapeutics 🇸🇪
MucoLife Therapeutics is redefining respiratory care with MLT-001, the first modern mucus-modulating therapy in over 60 years. Over 500 million people with COPD, cystic fibrosis, asthma, and bronchiectasis suffer from mucus plugs that drive infection, inflammation, and irreversible lung damage — a root cause untouched by current therapies.
Polku Therapeutics 🇫🇮
Polku Therapeutics is pioneering a novel therapeutic strategy that breaks the vicious cycle of tau pathology by reactivating the neuron’s own tau-clearing machinery. Their small-molecule drug candidates target the PREP-PTPA–PP2A complex, an important regulatory node that governs tau phosphorylation, aggregation, and clearance.
PreTT ApS 🇩🇰
PreTT is developing the next-generation Pretargeted Radioligand Therapy (PRLT) platform for solid cancer theranostics. PreTT’s approach represents a paradigm shift in radiopharmaceuticals, combining the precision of biologics with the therapeutic power of targeted radiation to deliver safer, more effective cancer therapies.
Rab Diagnostics AS 🇳🇴
RabDx is developing a biomarker-based diagnostic platform, RabCANCER, to guide cancer treatment with antibody drug conjugates (ADCs). RabCANCER harbours different products used to identify their novel biomarkers in samples from the patient`s tumour and thereby predict ADC response.
Serendo Therapeutics AB 🇸🇪
Serendo Therapeutics AB (Serendo) is developing a breakthrough therapeutic platform targeting Endophilin A2 (EA2) to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and lupus. Their mission is to deliver safer, more durable, and accessible medicines for patients and reduce the burden these diseases place on healthcare systems.
Vesper Bio 🇩🇰
Vesper Bio is a private, VC-backed, clinical stage company, world-leading in sortilin biology. Sortilin is an exciting novel target involved in many neurodegenerative diseases. Our lead candidate VES001 has been developed for the monogenetic disease called FTD-GRN, a rare disease type of frontotemporal dementia (FTD).